Nia Haware and Marcia Pennant work jointly as Legacy Marketing Officers in our Development and Communications Office.

The Institute of Cancer Research, London, is the joint recipient of a major new Medical Research Council (MRC) grant to advance how sensitive medical imaging data can be used for research. This award ...

New research presents clear guidelines on how patient-reported outcomes (PROs) can be used more effectively in early-stage cancer drug trials, helping ensure that patient experiences meaningfully ...

The Institute of Cancer Research, London, welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the targeted drug talazoparib (trade name Talzenna), in ...

A blood test can predict how well patients with advanced breast cancer will respond to targeted therapies – before treatment begins, according to new research. A team from The Institute of Cancer ...

The Institute of Cancer Research, London has welcomed the announcement by NHS England that the lifesaving drug abiraterone has been approved for use on the NHS for men in England with prostate cancer ...

Tens of thousands of tumour samples which have been stored in the basement of a London hospital for more than 70 years could be the key to unlocking the mystery of why bowel cancer cases are rising in ...

Experts at The Institute of Cancer Research, London, have responded to the draft recommendation from the National Screening Committee (NSC) to implement a targeted prostate cancer screening programme ...

Today, the first men have been invited to join the ambitious £42 million TRANSFORM screening trial, kicking off the biggest prostate cancer screening study in a generation. The trial will test the ...

Scientists have identified a more accurate way of predicting which patients with multiple myeloma, a type of blood cancer, are likely to relapse early following treatment. A study carried out by a ...

Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, ...